Qiao, Yuanyuan
Choi, Jae Eun
Tien, Jean C.
Simko, Stephanie A.
Rajendiran, Thekkelnaycke
Vo, Josh N.
Delekta, Andrew D.
Wang, Lisha
Xiao, Lanbo
Hodge, Nathan B.
Desai, Parth
Mendoza, Sergio
Juckette, Kristin
Xu, Alice
Soni, Tanu
Su, Fengyun
Wang, Rui
Cao, Xuhong
Yu, Jiali
Kryczek, Ilona http://orcid.org/0000-0002-3130-2533
Wang, Xiao-Ming
Wang, Xiaoju
Siddiqui, Javed
Wang, Zhen
Bernard, Amélie
Fernandez-Salas, Ester
Navone, Nora M.
Ellison, Stephanie J.
Ding, Ke
Eskelinen, Eeva-Liisa http://orcid.org/0000-0003-0006-7785
Heath, Elisabeth I. http://orcid.org/0000-0003-1381-2713
Klionsky, Daniel J. http://orcid.org/0000-0002-7828-8118
Zou, Weiping http://orcid.org/0000-0001-7952-3549
Chinnaiyan, Arul M. http://orcid.org/0000-0001-9282-3415
Funding for this research was provided by:
Prostate Cancer Foundation (Young Investigator Award, Young Investigator Award, Challenge Award)
U.S. Department of Defense (W81XWH-16-1-0195, PC130151P1, PC130151P1)
U.S. Department of Health & Human Services | National Institutes of Health (GM131919)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P50CA186786, R35CA231996)
Article History
Received: 17 September 2020
Accepted: 17 June 2021
First Online: 2 August 2021
Competing interests
: The University of Michigan has filed a disclosure on the findings based on this study. A.M.C. and Y.Q. are named as co-inventors on the disclosure. Esanik Therapeutics licensed ESK981 from Teva Pharmaceuticals. A.M.C. is a co-founder of Esanik Therapeutics and serves on its scientific advisory board. Neither Esanik Therapeutics nor Teva Pharmaceuticals was involved in the design or approval of this study, nor was this study funded by them. The remaining authors declare no competing interests.